Melphalan flufenamide
11th November 2018
Unassigned
New Medicines
Ygalo · Relapsed or refractory multiple myeloma (MM) - in combination with dexamethasone for adults who have received at least two prior treatment regimens, including both lenalidomide and a proteasome inhibitor
Information
Ygalo
New molecular entity
Oncopeptides
Oncopeptides
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes
Category
Prodrug of melphalan and an alkylating peptide that stimulates caspase-3 and inhibits DNA synthesis
The incidence in Europe is 4.5-6.0 per 100,000/year with a mortality rate of 4.1 per 100,000/year [1]. ·
Relapsed or refractory multiple myeloma (MM) - in combination with dexamethasone for adults who have received at least two prior treatment regimens, including both lenalidomide and a proteasome inhibitor
Intravenous infusion